SC14D9C

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

SOLICITATION/RECOMMENDATION STATEMENT

UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

ABIOMED, INC.

(Name of Subject Company)

ABIOMED, INC.

(Name of Person(s) Filing Statement)

Common stock, par value $0.01 per share

(Title of Class of Securities)

003654100

(CUSIP Number of Class of Securities)

Michael R. Minogue

Chairman, President and Chief Executive Officer

ABIOMED, Inc.

22 Cherry Hill Drive

Danvers, Massachusetts 01923

(978) 646-1400

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person(s) Filing Statement)

With copies to:

Robert W. Downes

Matthew G. Hurd

Sullivan & Cromwell LLP

125 Broad Street

New York, New York 10004

(212) 558-4000

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Schedule 14D-9 filing consists of certain communications relating to the proposed acquisition of ABIOMED, Inc., a Delaware corporation (the “Company”), by Johnson & Johnson, a New Jersey corporation (“Parent”), and Athos Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), pursuant to the terms and subject to the conditions of an Agreement and Plan of Merger, dated as of October 31, 2022, by and among the Company, Parent and Merger Sub.

1.	Exhibit 99.1: Email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
2.	Exhibit 99.2: Follow-up email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
3.	Exhibit 99.3: Q&A Document for Employees, hyperlinked in email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
4.	Exhibit 99.4: Abiomed Operating Procedures United States Version, transcript of video hyperlinked in email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
5.	Exhibit 99.5: Abiomed Four Principles Animation United States Version 2021, transcript of video hyperlinked in email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
6.	Exhibit 99.6: “I am Abiomed. I am Heart Recovery” Transcript, transcript of video hyperlinked in email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
7.	Exhibit 99.7: Approved Supplier Messaging Kit.
8.	Exhibit 99.8: Approved Physician Messaging Kit.
9.	Exhibit 99.9: Approved Government or Association Messaging Kit.
10.	Exhibit 99.10: Approved Business Partner Messaging Kit.

Items #1-10 listed above were first used or made available on November 1, 2022.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of the Company. At the time the offer is commenced, Parent and Merger Sub will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission (the “SEC”), and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The Company stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of the Company. In addition, all of these materials (and all other materials filed by the Company with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by the Company at https://investors.abiomed.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for the Company’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of the Company’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from the Company’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of the Company into Parent subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of the Company’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the SEC by the Company, including the Company’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by the Company and the tender offer documents to be filed by Parent and Merger Sub. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

The Company is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as required by law.

Exhibit No.	Description
99.1	Email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
99.2	Follow-up email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
99.3	Q&A Document for Employees, hyperlinked in email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November  1, 2022.
99.4	Abiomed Operating Procedures United States Version, transcript of video hyperlinked in email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
99.5	Abiomed Four Principles Animation United States Version 2021, transcript of video hyperlinked in email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
99.6	“I am Abiomed. I am Heart Recovery” Transcript, transcript of video hyperlinked in email from Michael Minogue, Chairman, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated November 1, 2022.
99.7	Approved Supplier Messaging Kit.
99.8	Approved Physician Messaging Kit.
99.9	Approved Government or Association Messaging Kit.
99.10	Approved Business Partner Messaging Kit.

EX-99.1

Exhibit 99.1

Please scroll down to read this message in German and Japanese.

Bitte scrollt nach unten, um diese Nachricht auf Deutsch zu lesen.

日本語メッセージは下にスクロールダウンしてご覧ください

Hello Everyone,

Moments ago, in a joint press release [LINK: https://www.businesswire.com/news/home/20221101005752/en/Johnson-Johnson-to-Acquire-Abiomed] from Abiomed and Johnson & Johnson it was announced that an agreement has been reached for Johnson & Johnson to acquire Abiomed. While it may take a couple of months or more for the transaction to close, it is very likely we are heading down this path to join an impressive global company. As you would expect, I have many emotions surrounding this decision. I would like to share with you the reasons why I and the Abiomed Board of Directors believe this is the right decision, at the right time, with the right partner to secure our future and position as the leader in heart recovery.

Specifically, I would like to highlight four points:

1. The acquisition puts Patients First. Combining Abiomed’s proven technology and talented, dedicated team of employees with Johnson & Johnson’s global scale, financial strength, robust clinical expertise and manufacturing expertise will accelerate our timeline for heart recovery for patients all over the world. Per the agreement, Johnson & Johnson has committed to completing the most comprehensive randomized controlled trials (RCTs) ever done for high-risk PCI, STEMI and cardiogenic shock with our PROTECT IV, STEMI DTU and RECOVER IV RCTs respectively.

2. Abiomed and Johnson & Johnson have similar cultures centered around patients and integrity. The companies have common values, purpose and a Patients First mindset. We have the I Am Abiomed Patients First Commitment [LINK: https://www.youtube.com/watch?v=3qWW46xKgb0]. Johnson & Johnson has “Our Credo,” which puts the needs and well-being of the people the company serves first. I encourage you to take a few minutes to read the Johnson & Johnson Credo at this link [LINK: https://www.jnj.com/credo/]. Furthermore, both companies have a “servant leadership” philosophy that empowers employees and values teamwork and innovation. These similarities were evident in the due diligence process and will ensure we move forward together while sustaining our winning culture. I also have confidence in and admiration for Johnson & Johnson’s CEO, Joaquin Duato, Executive Chairman Alex Gorsky, and Executive Vice President and Worldwide Chairman of MedTech Ashley McEvoy.

3. The acquisition grows shareholder value, one of our four guiding principles. Upon closing, this transaction will deliver a significant cash value for Abiomed shareholders. For employee shareholders, this includes vested and unvested shares and options. Approximately 80% of Abiomed employees own Abiomed stock.

4. The acquisition retains Abiomed as an entity and creates opportunities for Abiomed employees. The Abiomed entity will remain standalone in pursuit of our goals reporting into and supported by Johnson & Johnson [LINK: https://www.jnjmedtech.com/en-US/at-a-glance] MedTech. Abiomed will be the foundation as Johnson & Johnson leverages our presence in the cath lab, heart surgery suite and every ICU/CCU at hospitals world-wide. This maintains continuity and stability for Abiomed employees, while, over time, giving employees access to career growth opportunities that only a company of Johnson & Johnson’s size can provide. Johnson & Johnson has consistently been an employer of choice and earned that reputation by investing in its employees and being a steward for its communities.

Abiomed will be a wholly owned subsidiary of Johnson & Johnson, which means my role as Abiomed Chairman and CEO will no longer exist. So, after nearly 19 years, it is with both personal sadness and excitement for the integration that I am announcing, I will no longer be your Chairman and CEO when the acquisition closes. However, I am very proud to announce that at the close, the leadership of Abiomed will transition to Andrew Greenfield, who will be the next president and leader of the company.

Per the best-selling author Jim Collins, all good CEOs and boards prepare for succession planning by developing strong leaders and creating an inspiring culture throughout the organization. We have built an incredible global team at all levels who have my full confidence. Andrew has been with Abiomed for 17 years and currently serves as our Executive Vice President and Chief Commercial Officer. He has the experience, intellect, and mental toughness to lead us into the future. He has a track record of adapting and executing while delivering results. And Andrew leads with poise, integrity and empathy.

Together we have created our Patients First Commitment [LINK: https://www.youtube.com/watch?v=3qWW46xKgb0], Four Principles [LINK: https://www.youtube.com/watch?v=wWcueU6xd4o] and Heartbeat Operating Procedures [LINK: https://www.youtube.com/watch?v=x333cmxZya8] – our WHY, WHAT and HOW. You are ready to continue the mission and achieve our vision.

More information will continue in the days ahead and acquisitions like this typically take several months for regulatory and legal approval. During the transition period stay focused on your FY23 goals, especially on innovation, clinical research and patient outcomes.

At Abiomed, we Dream Big and Execute Bigger. For years, we have dreamed of making heart recovery the standard of care for patients all over the world. Combining the resources of Abiomed and Johnson & Johnson will allow us to make this dream come true faster than we ever thought possible.

I am Abiomed.

Patients First!

Mike

Liebe Kolleginnen und Kollegen,

vor wenigen Augenblicken wurde in einer gemeinsamen Pressemitteilung [LINK: https://www.businesswire.com/news/home/20221101005752/en/Johnson-Johnson-to-Acquire-Abiomed] von Abiomed und Johnson & Johnson bekannt gegeben, dass eine Vereinbarung zur Übernahme von Abiomed durch Johnson & Johnson getroffen wurde. Es kann zwar noch einige Monate dauern, bis die Transaktion abgeschlossen ist, aber es ist sehr wahrscheinlich, dass wir diesen Weg einschlagen und uns einem beeindruckenden globalen Unternehmen anschließen werden. Wie Ihr Euch denken könnt, bin ich von dieser Entscheidung sehr bewegt. Ich möchte Euch die Gründe darlegen, warum ich und der Vorstand von Abiomed der Meinung sind, dass dies die richtige Entscheidung zum richtigen Zeitpunkt und mit dem richtigen Partner ist, um unsere Zukunft und unsere Position als Marktführer im Bereich der Herzgenesung zu sichern.

Im Einzelnen möchte ich vier Punkte hervorheben:

1. Bei der Übernahme stehen die Patienten an erster Stelle. Die Kombination der bewährten Technologie und des talentierten, engagierten Mitarbeiterteams von Abiomed mit der globalen Größe, der Finanzkraft, dem soliden klinischen Fachwissen und dem Fertigungs-Know-how von Johnson & Johnson wird unseren Zeitplan für die Genesung des Herzens für Patienten auf der ganzen Welt beschleunigen. Im Rahmen der Vereinbarung hat sich Johnson & Johnson verpflichtet, mit den RCTs PROTECT IV, STEMI DTU und RECOVER IV die umfassendsten, randomisierten und kontrollierten Studien (RCTs) durchzuführen, die jemals für Hochrisiko-PCI, STEMI und kardiogenen Schock durchgeführt wurden.

2. Abiomed und Johnson & Johnson haben eine verwandte Kultur, in deren Mittelpunkt Patienten und Integrität stehen. Die Unternehmen haben gemeinsame Werte, Ziele und eine Einstellung, bei der die Patienten an erster Stelle stehen. Wir haben das I Am Abiomed Patients First Commitment [LINK: https://www.youtube.com/watch?v=3qWW46xKgb0]. Johnson & Johnson hat „Unser Credo“, das die Bedürfnisse und das Wohlergehen der Menschen, denen das Unternehmen dient, an die erste Stelle setzt. Ich empfehle Ihnen, sich ein paar Minuten Zeit zu nehmen und das Johnson & Johnson-Credo [LINK: https://www.jnjmedtech.com/de-DE/OurCredo] unter diesem Link [LINK: https://www.jnjmedtech.com/de-DE/OurCredo] zu lesen. Darüber hinaus verfolgen beide Unternehmen eine Philosophie der “unterstützenden Führung”, die die Mitarbeiter befähigt und Teamarbeit und Innovation schätzt. Diese Gemeinsamkeiten waren bei der Due-Diligence-Prüfung offensichtlich und werden dafür sorgen, dass wir gemeinsam vorankommen und gleichzeitig unsere erfolgreiche Unternehmenskultur beibehalten. Ich habe auch gleichzeitig Vertrauen in und Bewunderung für den CEO von Johnson & Johnson, Joaquin Duato, den Executive Chairman Alex Gorsky und den Executive Vice President und Worldwide Chairman von MedTech Ashley McEvoy.

3. Die Übernahme steigert den Shareholder Value, eines unserer vier Leitprinzipien. Nach Abschluss der Transaktion wird diese einen erheblichen Barwert für die Abiomed-Aktionäre darstellen. Für die Mitarbeiter-Aktionäre umfasst dies sowohl zugeteilte als auch nicht zugeteilte Aktien und Optionen. Ungefähr 80% der Abiomed-Mitarbeiter besitzen Abiomed-Aktien.

4. Bei der Übernahme bleibt Abiomed als eine Einheit erhalten und schafft gleichzeitig Perspektiven für die Mitarbeiter. Das Abiomed-Unternehmen wird eigenständig bleiben, um unsere Ziele weiter zu verfolgen, die wir an Johnson & Johnson MedTech [LINK: https://www.jnjmedtech.com/en-US/at-a-glance] berichten und die von Ihnen unterstützt werden. Abiomed wird die Grundlage sein, während Johnson & Johnson unsere Präsenz im Katheterlabor, in der Herzchirurgie und auf allen Intensivstationen in Krankenhäusern weltweit ausbaut. Dies gewährleistet Kontinuität und Stabilität für die Mitarbeiter von Abiomed und eröffnet ihnen im Laufe der Zeit Karrieremöglichkeiten, die nur ein Unternehmen der Größe Johnson & Johnsons bieten kann. Johnson & Johnson ist seit jeher ein renommierter Arbeitgeber und hat sich diesen Ruf durch Investitionen in seine Mitarbeiter und sein Engagement für seine Bezugsgruppen verdient.

Abiomed wird zu einer hundertprozentigen Tochtergesellschaft von Johnson & Johnson, was bedeutet, dass meine Rolle als Chairman und CEO von Abiomed nicht mehr existieren wird. Nach fast 19 Jahren kündige ich also mit persönlichem Bedauern, aber auch mit Freude über die Integration an, dass ich nach Abschluss der Übernahme nicht mehr Euer Chairman und CEO sein werde. Ich bin jedoch sehr stolz darauf, dass die Leitung von Abiomed nach Abschluss der Übernahme an Andrew Greenfield übergehen wird, der der nächste Präsident und Leiter des Unternehmens sein wird.

Laut dem Bestsellerautor Jim Collins bereiten sich alle guten CEOs und Vorstände auf die Nachfolgeplanung vor, indem sie starke Führungskräfte entwickeln und eine inspirierende Kultur im gesamten Unternehmen schaffen. Wir haben ein unglaubliches, globales Team auf allen Ebenen aufgebaut, das mein volles Vertrauen genießt. Andrew ist seit 17 Jahren bei Abiomed tätig und fungiert derzeit als Executive Vice President und Chief Commercial Officer. Er hat die Erfahrung, den Intellekt und die mentale Stärke, um uns in die Zukunft zu führen. Er hat eine Erfolgsbilanz bei der Anpassung und Umsetzung von Maßnahmen und der Erzielung von Ergebnissen. Und Andrew führt mit Gelassenheit, Integrität und Einfühlungsvermögen.

Gemeinsam haben wir unser Engagement für die Patienten [LINK: https://www.youtube.com/watch?v=3qWW46xKgb0], unsere vier Grundsätze [LINK: https://www.youtube.com/watch?v=aYO1mOtBfkM] und unsere “Heartbeat Operating Procedures” [LINK: https://www.youtube.com/watch?v=bVt-224jcQo] entwickelt - unser WARUM, WAS und WIE. Ihr seid bereit, die Mission fortzusetzen und unsere Vision zu verwirklichen.

Weitere Informationen werden in den kommenden Tagen folgen. Akquisitionen wie diese benötigen in der Regel einige Monate für die behördliche und rechtliche Genehmigung. Konzentriert Euch während der Übergangsphase auf Eure Ziele für das GJ23, insbesondere auf Innovation, klinische Forschung und Patientenergebnisse.

Bei Abiomed denken wir groß und setzen noch größere Ziele um. Seit Jahren träumen wir davon, die Wiederherstellung des Herzens zum Standard in der Versorgung von Patienten auf der ganzen Welt zu machen. Die Kombination der Ressourcen von Abiomed und Johnson & Johnson wird es uns ermöglichen, diesen Traum schneller zu verwirklichen, als wir es je für möglich gehalten hätten.

Ich bin Abiomed.

Die Patienten stehen an erster Stelle!

Mike

***********************************************************************************

************************

皆さん、こんにちは。

先ほど、アビオメッドとジョンソン・エンド・ジョンソンの合同プレスリリース [LINK: https://www.businesswire.com/news/home/20221101005752/en/Johnson-Johnson-to-Acquire-Abiomed]で、ジョンソン・エンド・ジョンソンによるアビオメッド買収が合意に至ったことが発表されました。買収が完了するまでに数ヶ月以上を要するかもしれませんが、素晴らしいグローバル企業の仲間入りをする可能性が非常に高くなりました。ご想像の通り、この決断に関して皆さんは様々な感情を抱いているかと存じます。私やアビオメッド取締役会が、この決断がアビオメッドの将来と心機能回復のリーダーとしての地位を確立するために、適切な時期に、適切な相手と実施する正しい選択であると考える理由を、皆さんにお伝えします。

具体的に、次の4点を強調したいと思います。

1. この買収は患者さん第一の考えに基づいて実施されます。アビオメッドの実績ある技術、そして能力のある献身的な従業員の皆さんと、ジョンソン・エンド・ジョンソンのグローバル規模、財務力、強固な臨床に関する専門知識および製造に関する専門知識を組み合わせることにより、世界中の患者さんの心機能回復への道筋の拡大を加速させることができます。この買収により、ジョンソン・エンド・ジョンソンは、 PROTECT IV、STEMI DTU、RECOVER IVそれぞれの無作為化比較試験において、高リスクPCI、STEMI 、心原性ショックに対するこれまでにない包括的な無作為化比較試験（ RCT）を完了させることを約束したことになります。

2. アビオメッドとジョンソン・エンド・ジョンソンは 、患者さんと誠実さを第一に掲げるという共通した文化があります。両社は共通の価値観、目的、患者さん第一の考え方を持っています。アビオメッドは、「 I Am Abiomed Patients First Commitment [LINK: https://www.youtube.com/watch?v=3qWW46xKgb0]」を掲げています。ジョンソン・エンド・ジョンソンには「我が信条（ Our Credo）」があり、同社はサービスを提供する人々のニーズと幸福を第一に考えています。このリンクから、ジョンソン・エンド・ジョンソンのクレド [LINK: https://www.jnj.co.jp/jnj-group/our-credo]を数分間読んでみることをお勧めします。さらに、両社は従業員に力を与え、チームワークとイノベーションを大切にする「サーバントリーダーシップ」の理念を掲げています。これらの共通点はデューデリジェンスの過程で明らかになり、アビオメッドのウィニングカルチャーを持続させること、共に前進することを保証します。また、ジョンソン・エンド・ジョンソンの CEOであるホアキン・デュアト、エグゼクティブ・チェアマンのアレックス・ゴースキー、 MedTech担当エグゼクティブ・ヴァイス・プレジデント兼ワールドワイドチェアマンのアシュレイ・マクエボイを信頼し、また賞賛を送りたいと思っています。

3. この買収は、アビオメッドの４原則の 1つである株主価値の最大化をもたらすものです。本買収は、クロージング後、アビオメッドの株主に大きなキャッシュバリューをもたらすでしょう。従業員株主の場合、これには権利確定済みおよび未確定の株式およびオプションが含まれます。アビオメッドの従業員の約 8割がアビオメッドの株式を保有しています。

4. この買収により、アビオメッドは事業会社として存続し、アビオメッドの従業員に機会を創出します。アビオメッドは独立した事業会社として、ジョンソン・エンド・ジョンソンMedTech [LINK: https://www.jnjmedtech.com/en-US]にレポートし、サポートを受けながらゴールを追求します。ジョンソン・エンド・ジョンソンは、世界中の病院のカテ室、心臓手術室、 ICU/CCU におけるアビオメッドのプレゼンスを活用し基盤を構築していきます。これにより、アビオメッドの従業員は継続性と安定性を維持しながら、ジョンソン・エンド・ジョンソンのような規模の会社ならではのキャリアアップの機会を手に入れることができます。ジョンソン・エンド・ジョンソンは常に選ばれる雇用主であり、従業員への投資と地域社会における責務を担うことで、高い評価を得ています。

アビオメッドはジョンソン・エンド・ジョンソンの 完全子会社となるため、アビオメッド会長兼CEOとしての私の役割はなくなります。このため、個人的な寂しさと統合への興奮の両方を感じながら、買収が完了した時点で私が約 19年間にわたって務めた会長兼CEOを退任することを発表します。買収完了後、アビオメッドのリーダーシップは、次のプレジデント兼リーダーであるアンドリュー・グリーンフィールドが務めることを、私は大変誇りに思います。

ベストセラー作家のジム・コリンズによれば、優れたCEOや取締役会は、強力なリーダーを育成し、組織全体にインスピレーションを与える文化を創造することによって、後継者育成の準備をするのだそうです。私たちは、あらゆるレベルの素晴らしいグローバルチームを構築しており、私は彼らに全幅の信頼を寄せています。アンドリューはアビオメッドに 17年間在籍し、現在はエグゼクティブ・ヴァイス・プレジデント兼チーフ・コマーシャル・オフィサーとして活躍しています。彼は、私たちを未来に導くための経験、知性、精神的強さを備えています。彼は、結果を出しながら適応し、実行してきた実績があります。そして、アンドリューは、冷静さ、誠実さ、共感をもってリードしています。

私たちは、「アビオメッドの誓い- 患者さん第一 [LINK: https://www.youtube.com/watch?v=3qWW46xKgb0]」、「アビオメッド４原則 [LINK: https://www.youtube.com/watch?v=uHuiuAGzA9s]」、「心臓の鼓動-業務手順 [LINK: https://www.youtube.com/watch?v=C1lAmJ1iyEo]」そして、「なぜ」、「何を」、「どのように」、を共に創り上げてきました。皆さんは、このミッションを継続し、アビオメッドのビジョンを達成する準備ができています。

この買収は、通常、規制および法的承認に数ヶ月を要します。移行期間中は、 FY23の目標、特にイノベーション、臨床研究、患者さんの生存率の向上に集中してください。

アビオメッドでは、大きな夢を描き、より大きな実行をします。私たちは長年にわたり、心臓の回復を世界中の患者さんの標準的な治療とすることを夢見てきました。アビオメッドとジョンソン・エンド・ジョンソンのリソースを組み合わせることで、私たちはこの夢を想像以上に早く実現することができるでしょう。

アビオメッドで働く私はアビオメッドそのものです。

患者さん第一！

マイク・ミノーグ

Mike

Patients First!

Patienten stehen an erster Stelle!

Kanja-san Daiichi!患者さん第一 ,

Michael R. Minogue

Chairman, President and Chief Executive Officer

ABIOMED, Inc.

22 Cherry Hill Drive | Danvers, MA 01923

Office: 978.646.1810 | Fax: 978.777.8411

mminogue@abiomed.com

www.abiomed.com [abiomed.com]

Recovering Hearts. Saving Lives.

[abiomed-6.wistia.com]

Click to Watch Abiomed’s Corporate Presentation [LINK: https://abiomed-6.wistia.com/medias/43mhlzxcqk]

“Above all else, keep watch over your heart, for herein lie the wellsprings of life.” – Proverbs

CONFIDENTIALITY NOTICE: This email message and any attachments are confidential and may be privileged and are meant to be read by the intended recipient only. If you are not the intended recipient, please notify sender immediately and destroy all copies of this message and any attachments without reading or disclosing their contents. Thank you.

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the Securities and Exchange Commission (“SEC”)) will be available at no charge from the SEC through its website at www.sec.gov [LINK: https://www.sec.gov/]. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx [LINK: https://investors.abiomed.com/investors/financials/sec-filings/default.aspx].

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of

any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the SEC by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

EX-99.2

Exhibit 99.2

Please scroll down to read this message in German and Japanese.

Bitte scrollt nach unten, um diese Nachricht auf Deutsch zu lesen.

日本語メッセージは下にスクロールダウンしてご覧ください

Hello Everyone,

As promised at today’s all-employee meeting, below is additional information related to today’s news. Please review the Q&A document carefully. If you have additional questions, please send them to questions@abiomed.com and we will do our best to get them answered.

During this time of transition, stay focused on achieving, then exceeding your FY23 goals. Together, let’s make Q3 our best quarter ever for innovation, clinical research, HCP training, patient growth and improving outcomes for our patients.

This is our opportunity to accelerate becoming the global standard of care. It starts now.

Patients First!

Mike

• Click here [LINK: https://abiomed.box.com/s/2tfxa5f1adzfu5ef4ufus4lsmaeiy11e] for an employee Q&A document related to today’s news

• Click here [LINK: https://www.jnjmedtech.com/en-US/at-a-glance] for an overview of Johnson & Johnson MedTech

• Click here [LINK: https://www.jnjmedtech.com/en-US/impact] for learn about Johnson & Johnson MedTech’s impact on improving healthcare

• Click here [LINK: https://www.jnj.com/credo/] to read the Johnson & Johnson “Our Credo”

***************************************************************

Liebe Kolleginnen und Kollegen,

wie auf der heutigen Mitarbeiterversammlung versprochen, findet Ihr nachstehend zusätzliche Informationen zu den heutigen Nachrichten. Bitte lest das Q&A-Dokument sorgfältig durch. Wenn Ihr weitere Fragen habt, sendet diese bitte an questions@abiomed.com und wir werden unser Bestes tun, um sie zu beantworten.

Konzentriert Euch in dieser Zeit des Übergangs darauf, Eure Ziele für das GJ23 zu erreichen und zu übertreffen. Lasst uns gemeinsam das 3. Quartal zum besten Quartal aller Zeiten in den Bereichen Innovation, klinische Forschung, Schulung von medizinischen Fachkräften, Patientenwachstum und Verbesserung der Ergebnisse für unsere Patienten machen.

Dies ist unsere Chance, schneller zum weltweiten Standard der Pflege zu werden. Es beginnt jetzt.

Die Patienten stehen an erster Stelle!

Mike

• Klickt hier, [LINK: https://abiomed.box.com/s/2tfxa5f1adzfu5ef4ufus4lsmaeiy11e] für ein Dokument mit Fragen und Antworten für Mitarbeiter zu den heutigen Nachrichten

• Klickt hier, [LINK: https://www.jnjmedtech.com/en-US/at-a-glance] um einen Überblick über Johnson & Johnson MedTech zu erhalten

• Klickt hier, [LINK: https://www.jnjmedtech.com/en-US/impact] um mehr über den Einfluss von Johnson & Johnson MedTech auf die Verbesserung der Gesundheitsversorgung zu erfahren

• Klickt hier, [LINK: https://www.jnjmedtech.com/de-DE/OurCredo] um das Johnson & Johnson Credo zu lesen

***********************************************************

皆さん、こんにちは。

本日の全社員ミーティングでお約束しましたとおり、本日のニュースに関する追加情報を以下に掲載します。 Q&Aをご覧ください。 ご質問は、questions@abiomed.com までお寄せください。

移行期間中は、FY23の目標を達成し、その目標を上回ることに集中しましょう。 第3四半期は、イノベーション、クリニカルリサーチ、HCPトレーニング、患者数の増加、患者さんの予後改善において、これまでで最高の四半期となるよう、共に取り組んでいきましょう。

これは、世界で標準治療となることを加速するチャンスです。 今がその始まりです。

患者さん第一！

マイク・ミノーグ

• 本日のニュースに関する社員向け Q&Aはこちら [LINK: https://abiomed.box.com/s/2tfxa5f1adzfu5ef4ufus4lsmaeiy11e]

• ジョンソン・エンド・ジョンソン メディカルカンパニー（MedTech）の概要はこちら （日本語）[LINK: https://www.jnjmedtech.com/ja-JP]

• ジョンソン・エンド・ジョンソン メディカルカンパニー（MedTech）のヘルスケア業界に与えるインパクトは こちら（英語のみ）[LINK: https://www.jnjmedtech.com/en-US/impact]

• ジョンソン・エンド・ジョンソンの「我が信条（Our Credo）」はこちら（日本語）[LINK: https://www.jnj.co.jp/jnj-group/our-credo]

Patients First!

Patienten stehen an erster Stelle!

Kanja-san Daiichi! 患者さん第一 ,

Michael R. Minogue

Chairman, President and Chief Executive Officer

ABIOMED, Inc.

22 Cherry Hill Drive | Danvers, MA 01923

Office: 978.646.1810 | Fax: 978.777.8411

mminogue@abiomed.com

www.abiomed.com

Recovering Hearts. Saving Lives.

Click to Watch Abiomed’s Corporate Presentation [LINK: https://abiomed-6.wistia.com/medias/43mhlzxcqk]

“Above all else, keep watch over your heart, for herein lie the wellsprings of life.” – Proverbs

CONFIDENTIALITY NOTICE: This email message and any attachments are confidential and may be privileged and are meant to be read by the intended recipient only. If you are not the intended recipient, please notify sender immediately and destroy all copies of this message and any attachments without reading or disclosing their contents. Thank you.

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the Securities and Exchange Commission (“SEC”)) will be available at no charge from the SEC through its website at www.sec.gov [LINK: https://www.sec.gov/]. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx. [LINK: https://investors.abiomed.com/investors/financials/sec-filings/default.aspx]

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the SEC by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

EX-99.3

Exhibit 99.3

Please scroll down to read this message in German and Japanese.

Bitte scrollt nach unten, um diese Nachricht auf Deutsch zu lesen.

日本語メッセージは下にスクロールダウンしてご覧ください

Q&A Document for Employees

This Q&A document is intended to answer some of the questions you may have about the pending acquisition of Abiomed by Johnson & Johnson. Keep in mind, the process is at an early stage. Information could change and new information could become available.

1. What was announced today?

Abiomed and Johnson & Johnson have reached an agreement for Johnson & Johnson to acquire Abiomed. Once the acquisition receives regulatory approval and is finalized, Abiomed will become a business owned by Johnson & Johnson and will operate as a standalone business unit within Johnson & Johnson MedTech. Abiomed employees will become part of the Johnson & Johnson organization.

Shortly after the acquisition closes, Abiomed stockholders, including employees who are stockholders, will receive $380 in cash for each share of Abiomed common stock they own, plus a contingent value right with a maximum payout of $35 upon achievement of certain commercial and regulatory milestones.

2. What is an acquisition?

An acquisition is when one company purchases another company.

3. When will this acquisition be completed?

Acquisitions like this one require regulatory approval and may take a number of months to finalize and close. The parties expect this transaction to close in Q1 of calendar year 2023.

4. What does the acquisition mean for our patients?

Combining Abiomed and Johnson & Johnson puts Patients First by accelerating our ability to recover hearts, save lives and provide patients around the world with the care they need.

5. What role will Mike Minogue have in the combined company?

Following the acquisition, Mike Minogue will serve as an advisor to assure a smooth transition. Abiomed’s current chief commercial officer, Andrew Greenfield, will run the standalone Abiomed business within Johnson & Johnson MedTech.

6. What will happen to Abiomed’s executive team?

Andrew Greenfield will run the standalone Abiomed business within Johnson & Johnson MedTech. He will be building out his executive leadership team over the coming weeks and months.

7. What will happen to Abiomed’s Board of Directors?

The Abiomed Board of Directors will no longer exist because Abiomed will no longer be a publicly traded company.

8. What will it be like to work at the combined company?

Johnson & Johnson and Abiomed are creating the global leader in cardiac and pulmonary interventional technology, and accelerating Abiomed’s path to making heart recovery the global standard of care. Together, we will have more resources and be better positioned for global growth and to advance our shared mission of improving outcomes for patients, recovering hearts and saving lives.

Johnson & Johnson and Abiomed’s cultures are very much aligned, sharing a Patients First approach. The companies have complementary values and common business philosophies. Both companies empower employees and value teamwork and innovation.

Johnson & Johnson values Abiomed’s accomplishments and its people, which will mean greater long-term opportunities as our growth continues. Starting at the top with Andrew Greenfield leading the standalone organization, Johnson & Johnson has reinforced its goal of ongoing continuity and stability for the majority of Abiomed people. Abiomed employees will be part of an organization that values our groundbreaking work and will support ongoing advancements in recovering hearts and saving lives. Johnson & Johnson has earned its reputation as an employer of choice by investing in its employees.

9. Will there be layoffs?

Under Johnson & Johnson we will continue our investments in our product pipeline, our clinical trials and our people. The standalone structure and Andrew Greenfield’s leadership will enable continuity, stability, and continuation for the majority of Abiomed employees.

Abiomed leadership will be transparent and communicate with you regularly throughout the transition process. No matter what happens, employees will be treated fairly and respectfully.

10. Will my job responsibilities or reporting structure change?

For the foreseeable future, it is business as usual. We will continue to work toward achieving our FY23 goals and improving outcomes for our patients. We do not anticipate any significant changes in job responsibilities or reporting structure for the majority of employees.

11. Will anything change between now and the acquisition closing?

Abiomed will continue to operate independently until the transaction closes. During this time, continue to put Patients First by working to achieve your FY23 goals and improving outcomes for patients.

12. Will we still be called Abiomed?

Yes.

13. Will Abiomed’ Four Principals, Heartbeat Operating Procedures, I Am Abiomed Patients First commitment, “Just Do It” philosophy and AARs continue?

Yes.

14. Will Abiomed maintain its current offices and manufacturing facilities?

Yes.

15. Will Abiomed continue to offer 24x7 onsite, on the phone and online support to hospitals?

Yes. The service we provide our customers and patients will remain one of Abiomed’ key differentiators.

16. Will employee benefits change?

For the foreseeable future, you will remain on Abiomed’ benefits program. But it is expected at some point, Abiomed employees will transition to Johnson & Johnson’s benefit program.

17. Should U.S. employees still do open enrollment?

Yes. U.S. employees should complete their open enrollment prior to November 11.

18. Will my current work scheduling continue?

Yes.

19. Do my FY23 goals stay the same? Will we be having our end-of-fiscal year review process in April?

Yes.

20. What happens to my unvested equity? What about my awards that already vested?

Unvested Abiomed equity will automatically vest when the acquisition closes and be paid to stockholders in cash, plus a contingent value right for each share underlying such equity. Vested equity will also be paid in cash plus a contingent value right.

21. Will I receive Abiomed stock in the future?

Upon the closing of the transaction, Abiomed will cease to exist as a publicly traded company and will no longer have stock.

22. Will Abiomed continue to invest in research and development (R&D) and clinical trials?

Yes. Abiomed’s substantial investments in research and development and clinical trials (including the randomized controlled trials for Impella) will continue. In fact, Abiomed’ strong R&D and clinical trial programs is one of the key reasons why Johnson & Johnson is acquiring Abiomed.

23. Will Abiomed traditions and employee celebrations continue?

Yes. Abiomed’s culture, traditions and employee events will continue.

24. Will Abiomed continue to have patient events?

Yes. Johnson & Johnson shares Abiomed’s commitment to putting Patients First. Our patients remain our WHY and we will continue to foster a strong patient program that includes regular virtual and in-person visits from patients.

25. Will Abiomed continue to support local communities and organizations?

Yes. In fact, Johnson & Johnson prides itself on employee volunteerism and support of its local communities.

26. What should I say if I’m contacted by the media or investors about the transaction?

Please don’t answer any questions from the media or investors. Direct the media to contact Tom Langford at tlangford@abiomed.com. Direct investors to contact Todd Trapp at ttrapp@abiomed.com.

27. Will I be kept informed as the acquisition goes through regulatory approval?

Yes. A number of steps must be completed over the next few months before transaction is finalized. Abiomed will be making public filings as required with respect to the status of the transaction.

28. What if I have additional questions?

Abiomed employees who have additional questions should email them to questions@abiomed.com.

***

Das Q&A-Dokument soll einige der Fragen beantworten, die Ihr möglicherweise zur bevorstehenden Übernahme von Abiomed durch Johnson & Johnson habt. Bedenkt bitte, dass sich der Prozess noch in einem frühen Stadium befindet. Informationen können sich ändern und neue Informationen können verfügbar werden.

1. Was wurde heute bekannt gegeben?

Abiomed und Johnson & Johnson haben eine Vereinbarung über die Übernahme von Abiomed durch Johnson & Johnson getroffen. Sobald die Übernahme von den Aufsichtsbehörden genehmigt und abgeschlossen ist, wird Abiomed ein Unternehmen im Besitz von Johnson & Johnson sein und soll als eigenständige Geschäftseinheit innerhalb von Johnson & Johnson betrieben werden. Die Mitarbeiter von Abiomed werden Teil der Johnson & Johnson-Organisation.

Kurz nach Abschluss der Übernahme werden die Abiomed-Aktionäre, einschließlich der Mitarbeiter, die Aktionäre sind, 380 US-Dollar in bar für jede Abiomed-Stammaktie erhalten, die sie besitzen, sowie ein bedingtes Wertrecht mit einer maximalen Auszahlung von 35 US-Dollar bei Erreichen bestimmter kommerzieller und regulatorischer Meilensteine.

2. Was ist eine Akquisition?

Eine Akquisition liegt vor, wenn ein Unternehmen ein anderes Unternehmen aufkauft.

3. Wann wird diese Übernahme abgeschlossen sein?

Übernahmen wie diese bedürfen der behördlichen Genehmigung und können einige Monate in Anspruch nehmen, bis sie abgeschlossen sind. Die Parteien gehen davon aus, dass diese Transaktion im 1. Quartal 2023 abgeschlossen sein wird.

4. Was bedeutet die Übernahme für unsere Patienten?

Durch den Zusammenschluss von Abiomed und Johnson & Johnson stehen die Patienten an erster Stelle, da wir schneller in der Lage sind, Herzen wiederherzustellen, Leben zu retten und Patienten auf der ganzen Welt die notwendige Versorgung zukommen zu lassen.

5. Welche Rolle wird Mike Minogue in dem fusionierten Unternehmen einnehmen?

Nach der Übernahme wird Mike Minogue als Berater fungieren, um einen reibungslosen Übergang zu gewährleisten. Der derzeitige Chief Commercial Officer von Abiomed, Andrew Greenfield, wird das eigenständige Abiomed-Geschäft innerhalb von Johnson & Johnson MedTech leiten.

6. Was wird aus dem Führungsteam von Abiomed?

Andrew Greenfield wird das eigenständige Abiomed-Geschäft innerhalb von Johnson & Johnson MedTech leiten. Er wird sein Führungsteam in den kommenden Wochen und Monaten zusammenstellen.

7. Was wird mit dem Vorstand von Abiomed geschehen?

Der Vorstand von Abiomed wird nicht mehr existieren, da Abiomed kein börsennotiertes Unternehmen mehr sein wird.

8. Wie wird es sein, in dem fusionierten Unternehmen zu arbeiten?

Johnson & Johnson und Abiomed erschaffen gemeinsam den Weltmarktführer im Bereich der interventionellen Herz- und Lungentechnologie. Diese Übernahme beschleunigt damit den Weg von Abiomed, die Herzheilung zum weltweiten Standard der Patientenversorgung zu machen. Gemeinsam werden wir über mehr Ressourcen verfügen und besser positioniert sein, um weltweit zu wachsen und unsere gemeinsame Mission voranzutreiben, nämlich die Ergebnisse für Patienten zu verbessern, Herzen zu retten und Leben zu retten.

a. Die Kulturen von Johnson & Johnson und Abiomed sind sehr eng miteinander verbunden und verfolgen den Ansatz “Patient first”. Die Unternehmen haben komplementäre Werte und gemeinsame Geschäftsphilosophien. Beide Unternehmen zeichnen sich durch einen Unternehmergeist aus, der die Mitarbeiter befähigt und Teamarbeit und Innovation schätzt.

b. Johnson & Johnson schätzt die Errungenschaften von Abiomed und seine Mitarbeiter, was langfristig größere Chancen für unser weiteres Wachstum bedeuten wird. Mit Andrew Greenfield an der Spitze der eigenständigen Organisation hat Johnson & Johnson sein Ziel der Kontinuität und Stabilität für die große Mehrheit der Abiomed-Mitarbeiter bekräftigt. Die Mitarbeiter von Abiomed werden Teil einer Organisation sein, die unsere bahnbrechende Arbeit schätzt und die kontinuierlichen Fortschritte bei der Wiederherstellung von Herzen und der Rettung von Leben unterstützen wird. Johnson & Johnson hat sich seinen Ruf als bevorzugter Arbeitgeber durch Investitionen in seine Mitarbeiter erworben.

c. Abiomed wird ein wichtiger Teil von Johnson & Johnson sein. Impella ist die am meisten untersuchte Herzpumpe in der Geschichte der FDA mit exklusiven Zulassungen mit den Attributen sicher und wirksam. Abiomed führt mehrere randomisierte kontrollierte Studien durch, um die Richtlinien der Klasse I zu erreichen. Und unser IP-Portfolio gewinnt weiter an Stärke, da wir kleinere, intelligentere und besser vernetzte Technologien entwickeln.

9. Wird es zu Entlassungen kommen?

Die eigenständige Struktur und die Führung durch Andrew Greenfield werden Kontinuität, Stabilität und Fortführung für die große Mehrheit der Abiomed-Mitarbeiter ermöglichen. Unter Johnson & Johnson werden wir unsere Investitionen in unsere Produktpipeline, unsere klinischen Studien und unsere Mitarbeiter fortsetzen.

Darüber hinaus beschäftigt Johnson & Johnson weltweit 144.000 Mitarbeiter und hat im vergangenen Jahr 7.000 Vollzeitbeschäftigte hinzugewonnen. Die Übernahme schafft also enorme Karrieremöglichkeiten für die Mitarbeiter von Abiomed.

Die Führung von Abiomed wird sich während des gesamten Übergangsprozesses transparent verhalten und regelmäßig mit Ihnen kommunizieren. Egal, was passiert, die Mitarbeiter werden fair und respektvoll behandelt.

10. Werden sich meine Arbeitsaufgaben oder meine Berichtsstruktur ändern?

Für die große Mehrheit der Mitarbeiter sind keine wesentlichen Änderungen der Aufgabenbereiche oder der Berichtsstruktur zu erwarten. Für die absehbare Zukunft bleibt alles beim Alten. Wir werden weiterhin daran arbeiten, unsere Ziele für das GJ23 zu erreichen und die Ergebnisse für unsere Patienten zu verbessern.

11. Wird sich bis zum Abschluss der Übernahme etwas ändern?

Abiomed wird bis zum Abschluss der Transaktion weiterhin unabhängig arbeiten. In dieser Zeit werdet Ihr weiterhin die Patienten in den Mittelpunkt stellen, indem Ihr daran arbeiten, Eure Ziele für das GJ23 zu erreichen und die Ergebnisse für die Patienten zu verbessern.

12. Werden wir weiterhin Abiomed heißen?

Ja, der Name Abiomed wird beibehalten.

13. Werden die vier Abiomed-Prinzipien, die “Heartbeat Operating Procedures”, die “I Am Abiomed Patients First”-Verpflichtung, die “Just Do It”-Philosophie und die AARs weitergeführt?

Ja.

14. Wird Abiomed seine derzeitigen Büros und Produktionsstätten beibehalten?

Ja.

15. Wird Abiomed den Krankenhäusern weiterhin einen 24x7-Support vor Ort, per Telefon und online anbieten?

Ja. Der Service, den wir unseren Kunden und Patienten bieten, wird eines der Hauptunterscheidungsmerkmale von Abiomed bleiben.

16. Werden sich die Leistungen für die Mitarbeiter ändern?

Für die absehbare Zukunft werden Sie weiterhin das Leistungsprogramm von Abiomed in Anspruch nehmen. Es ist jedoch zu erwarten, dass die Mitarbeiter von Abiomed irgendwann in das Leistungsprogramm von Johnson & Johnson wechseln werden.

17. Müssen sich die US-Mitarbeiter noch anmelden?

Ja. US-Beschäftigte sollten ihre offene Anmeldung vor dem 11. November abschließen.

18. Bleibt unsere Politik der örtlich flexiblen Arbeit bestehen? Bleibt meine derzeitige Arbeitseinteilung bestehen?

Ja.

19. Bleiben meine Ziele für das GJ23 gleich? Werden wir im April unsere Überprüfung zum Ende des Geschäftsjahres durchführen?

Ja.

20. Was geschieht mit meinen nicht unverfallbaren Anteilen? Was ist mit meinen bereits unverfallbaren Anteilen?

Unverfallbare Abiomed-Aktien werden automatisch unverfallbar, wenn die Übernahme abgeschlossen ist, und werden den Aktionären in bar ausgezahlt, zuzüglich eines bedingten Wertrechts für jede Aktie, die diesen Aktien zugrunde liegt. Unverfallbare Aktien werden ebenfalls in bar ausgezahlt, zuzüglich eines bedingten Wertanspruchs.

21. Werde ich in Zukunft Abiomed-Aktien erhalten?

Mit dem Abschluss der Transaktion hört Abiomed auf, als börsennotiertes Unternehmen zu existieren und wird keine Aktien mehr haben.

22. Wird Abiomed weiterhin in Forschung und Entwicklung (F&E) und klinische Versuche investieren?

Ja. Die erheblichen Investitionen von Abiomed in Forschung und Entwicklung sowie in klinische Studien (einschließlich der randomisierten kontrollierten Studien für Impella) werden fortgesetzt. Die starken F&E- und klinischen Studienprogramme von Abiomed sind einer der Hauptgründe für die Übernahme von Abiomed durch Johnson & Johnson.

23. Werden die Abiomed-Traditionen und Mitarbeiterfeiern weitergeführt?

Ja. Die Kultur, die Traditionen und die Mitarbeiterveranstaltungen von Abiomed werden fortgesetzt.

24. Wird Abiomed auch unter der Eigentümerschaft von Johnson & Johnson weiterhin Patientenveranstaltungen durchführen?

Ja. Johnson & Johnson teilt das Engagement von Abiomed, die Patienten in den Mittelpunkt zu stellen. Unsere Patienten bleiben unser WARUM, und wir werden weiterhin ein starkes Patientenprogramm fördern, das regelmäßige virtuelle und persönliche Besuche von Patienten umfasst.

25. Wird Abiomed weiterhin lokale Gemeinschaften und Organisationen unterstützen?

Ja. Johnson & Johnson ist stolz auf das ehrenamtliche Engagement seiner Mitarbeiter und die Unterstützung seiner lokalen Gemeinschaften.

26. Was soll ich sagen, wenn ich von den Medien oder Investoren auf die Transaktion angesprochen werde?

Beantworten Sie bitte keine Fragen der Medien oder Investoren. Verweisen Sie die Medien an Tom Langford unter tlangford@abiomed.com. Weisen Sie Investoren an, Todd Trapp unter ttrapp@abiomed.com zu kontaktieren.

27. Werde ich auf dem Laufenden gehalten, während die Übernahme die behördliche Genehmigung durchläuft?

Ja. In den nächsten Monaten muss eine Reihe von Schritten vollzogen werden, bevor die Transaktion abgeschlossen werden kann. Abiomed wird bei Bedarf öffentliche Berichte über den Stand der Transaktion veröffentlichen.

28. Was ist, wenn ich weitere Fragen habe?

Abiomed-Mitarbeiter, die weitere Fragen haben, sollten diese per E-Mail an questions@abiomed.com richten.

***

このQ&Aは、ジョンソン・エンド・ジョンソンによるアビオメッドの買収について、皆さんからのご質問にお答えすることを目的としています。 この買収プロセスはまだ初期段階にあることを念頭に置いてください。情報が変更され、新しい情報が入手できる可能性があります。

1. 本日発表された内容は何ですか？

アビオメッドとジョンソン・エンド・ジョンソンは 、ジョンソン・エンド・ジョンソンがアビオメッドを買収することに合意しました。買収が規制当局の承認を得て確定した後、アビオメッドはジョンソン・エンド・ジョンソンが所有する事業会社となり、ジョンソン・エンド・ジョンソン MedTech内の独立したビジネスユニットとして運営されることになります。アビオメッドの社員は、ジョンソン・エンド・ジョンソンの組織の一員となります。

買収完了後、株主である従業員を含むアビオメッドの株主は、所有するアビオメッドの普通株式 1株につき380ドルの 現金と、特定の商業上および規制上のマイルストーンの達成時に臨時的権利として最大 35ドルを受け取ることになります。

2. 買収とは何ですか？

買収とは、企業が別の企業を取得（買収）することです。

3. いつこの買収は完了しますか？

この買収には規制当局の承認が必要であり、最終決定と完了には数カ月かかる可能性があります。両当事者は、本買収が 2023年の第1四半期（1月～3月）に完了することを期待しています。

4. 患者さんにとってこの買収はどのような意味がありますか？

アビオメッドとジョンソン・エンド・ジョンソンの 統合により、心臓の回復、救命、そして世界中の患者さんに必要な治療を提供する能力が加速され、患者さんを第一に考えることができるようになります。

5. 統合後、マイク・ミノーグはどのような役割を担いますか？

買収完了後は、マイク・ミノーグがアドバイザーを務め、スムーズな移行を保証します。アビオメッドの現コマーシャル最高責任者であるアンドリュー・グリーンフィールドは、ジョンソン・エンド・ジョンソン MedTech内の独立したアビオメッド事業会社をリードすることになります。

6. アビオメッドのエグゼクティブチームはどうなりますか ？

アンドリュー・グリーンフィールドは、ジョンソン・エンド・ジョンソンMedTech 内の独立したアビオメッド事業をリードすることになります。今後、数週間から数カ月かけて、経営陣の育成を行う予定です。

7. アビオメッドの取締役会はどうなりますか？

アビオメッドは株式公開会社ではなくなりますので、アビオメッドの取締役会は今後なくなります。

8. 買収後の会社での勤務はどうなりますか？

ジョンソン・エンド・ジョンソンとアビオメッドは 、心臓および肺のインターベンション技術におけるグローバルリーダーを生み出し、心臓の回復を世界標準の治療とするアビオメッドの道を加速させます。両社は、より多くのリソースを持ち、グローバルな成長に向けて、また、患者さんの予後を改善し、心臓を回復させ、命を救うという共通の使命を推進するために、より良いポジションを確立することができます。

ジョンソン・エンド・ジョンソンとアビオメッドの 文化は非常に一致しており、患者さんを第一に考える姿勢を持っています。両社はお互いに価値観を補完し合い、共通のビジネス哲学を有しています。両社は従業員に力を与え、チームワークとイノベーションを重視します。

ジョンソン・エンド・ジョンソンは、アビオメッドの業績とその人材を高く評価しており、これは私たちの成長に伴う長期的な機会の増大を意味します。ジョンソン・エンド・ジョンソンは、独立した組織を率いるアンドリュー・グリーンフィールドを筆頭に、アビオメッドの従業員の大半に継続的かつ安定した生活を提供するという目標を強化しています。アビオメッドの社員は、私たちの画期的な仕事を評価する組織の一員となり、心臓の回復と命を助けるための継続的な進歩をサポートすることになります。ジョンソン・エンド・ジョンソンは、従業員への投資により、選ばれる雇用主としての評判を得ています。

9. 解雇は行われますか？

ジョンソン・エンド・ジョンソンのもとで 、私たちは製品パイプライン、臨床試験、人材への投資を継続します。独立した組織とアンドリュー・グリーンフィールドのリーダーシップにより、アビオメッドの従業員の大半は継続性、安定性、そして継続性を確保することができます。

アビオメッドのリーダーシップは、移行期間中、透明性を保ち、定期的に皆さんとコミュニケーションを取っていく予定です。何が起ころうとも、従業員は公平かつ敬意を持って扱われます。

10. 職責やレポートライン・組織に変更はありますか？

当面は通常通りです。私たちは、 FY23の目標達成と患者さんの治療成績向上のために引き続き取り組んでまいります。大半の従業員は職務内容やレポートライン・組織に大きな変更はないと考えています。

11. 今後買収完了までの間に何か変更はありますか？

アビオメッドは、本買収が完了するまでは、引き続き独立した事業運営を行います。この間、 FY23の目標達成と患者さんの治療成績向上に努め、引き続き患者さんを第一に行動してください。

12. 今後もアビオメッドという名前で呼ばれますか？

はい。

13. アビオメッドの4原則、心臓の鼓動(業務手順)、アビオメッドの誓い（I Am Abiomed Patients First）、「Just Do It」の哲学、AARsは継続されるのでしょうか？

はい、そうです。

14. アビオメッドの現在のオフィスや製造拠点はそのまま維持されますか？

はい。

15. アビオメッドは、今後も24時間365日のオンサイト、電話、オンラインサポートを病院に提供するのでしょうか。

はい。お客様や患者さんに提供するサービスは、今後もアビオメッドの重要な差別化要因の 1つです。

16. 従業員へのベネフィットに変更はありますか？

当面の間、あなたはアビオメッドの福利厚生プログラムを利用することになります。 しかし、ある時点でアビオメッドの社員はジョンソン・エンド・ジョンソンの福利厚生プログラムに移行することが予想されます。

17. アメリカのアビオメッド従業員はオープンエンロールメントを行う必要がありますか？

はい。アメリカの従業員は、 11月11日までにオープンエンロールメントを完了させる必要があります。

18. 現在の業務のスケジュールは継続してよいですか？

はい。

19. FY23の目標に変更はありますか？年度末の評価は 4月に行われますか？

はい。

20. 権利確定していない株式はどうなりますか？すでに権利確定している報奨はどうなりますか？

権利確定していないアビオメッド株式は、買収が完了した時点で自動的に権利確定し、現金と、当該株式の基礎となる株式 1株あたりの成功報酬の権利で株主に支払われます。 権利確定した株式についても、現金に加え、権利放棄された株式が支払われます。

21. 将来、アビオメッドの株式を受け取ることができますか？

本買収の完了により、アビオメッドは上場企業ではなくなり、株式も保有しなくなります。

22. 研究開発や臨床試験への投資は継続しますか？

はい。研究開発および臨床試験（ Impellaの無作為化比較試験を含む）に対するアビオメッドの大規模な投資は今後も継続される予定です。実際、アビオメッドの強力な研究開発および臨床試験プログラムは、ジョンソン・エンド・ジョンソンがアビオメッドを買収する主な理由の一つです。

アビオメッドが伝統的に行っている社員イベントやお祝いは今後も続きますか？

はい。アビオメッドの文化、伝統、従業員イベントは継続されます

23. アビオメッドは今後も患者さんイベントを実施しますか？

はい。ジョンソン・エンド・ジョンソンは、患者さんを第一に考えるというアビオメッドのコミットメントを共有しています。私たちの患者さんは私たちの WHY（なぜ）であり続け、患者さんからの定期的なオンラインまたは直接の訪問を含む強力な患者さんプログラムを引き続き育成していきます。

24. アビオメッドはローカルコミュニティや 団体のサポートを今後も継続しますか？

はい。ジョンソン・エンド・ジョンソンも、従業員のボランティア活動や地域社会への支援に誇りを持っています。

25. この買収について報道関係者や投資家から質問があった場合、どのように答えればよいですか？

メディアや投資家からの質問には回答しないようにしてください。報道関係者からの問い合わせは、 Tom Langford（tlangford@abiomed.com）に連絡するように伝えてください。投資家の方は、Todd Trapp（ttrapp@abiomed.com）に問い合わせるよう伝えてください。

26. 買収が規制当局の承認を受けるまで、情報は提供されますか？

はい、買収が完了するまでには、今後数ヶ月の間に多くのステップを完了させなければなりません。アビオメッドは、本買収の状況について、必要に応じ、公的機関に提出する予定です。

27. その他に質問がある場合はどこに問い合わせればよいですか？

追加の質問がある場合は、 questions@abiomed.com までメールでお問い合わせください。

LEGEND FOR COMMUNICATIONS

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the Securities and Exchange Commission (“SEC”) by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

EX-99.4

Exhibit 99.4

Abiomed Operating Procedures United States Version

At Abiomed our patients are why we exist. They are our purpose. Our highest recognition of success is to recover and preserve our patients’ hearts so they can return home to their families.

Our four principals describe what we do. We recover hearts and save lives, lead in technology and innovation, grow shareholder value, and sustain a winning culture.

Our operating procedures describe how we do things. Our operating procedures are our heartbeat, continuously providing our path and guiding our execution. Everyone at Abiomed plays a role in keeping our heartbeat strong. We do this when we lead, manage, adapt and execute.

At Abiomed, we lead by inspiring others, developing vision and strategies that create positive change. As service leaders, we lead with integrity, purpose and mental toughness. Leaders ensure high standards are upheld, lead by example, and we hold each other accountable.

We also manage. Disciplined management of plans, processes and budgets brings accountability, which creates predictable results.

We also adapt. The ability to adapt is a key attribute of a learning organization like Abiomed. Communicating with each other, analyzing information in real time, and doing rigorous analysis. We also perform After Action Reviews to help us effectively adapt and pursue perfection and constant improvement.

Finally, we execute piloted programs with simplicity. We are guided by standard operating procedures for speed, which help us work together in unison. We are empowered to “just do it” when we understand our leaders’ intent and we can help our patients and customers. And we work together as a team with grit to get things done.

Like a heartbeat, Abiomed’s operating procedures continuously pulse through our organization. When we lead, manage, adapt and execute we create positive results, recover more hearts and save more lives. This is our heartbeat. This is how we execute at Abiomed.

EX-99.5

Exhibit 99.5

Abiomed Four Principles Animation United States Version 2021

Recovering hearts and saving lives is the founding principle and guiding compass of our organization. This is our highest recognition of success. Recovering and preserving our patients’ hearts and oxygenating their bodies enables them to return home to their families and enjoy an improved quality of life.

At Abiomed, we are leading in technology and innovation. We are committed to providing patients and health care providers with the highest quality devices and the optimal cost-effective solutions. We accomplish this through relentless exploration of new ideas and approaches that allow us to address new clinical challenges for our customers and patients.

Growing shareholder value rewards our investors and helps to ensure the company’s financial stability, allowing for the continued pursuit of our mission. Shareholder value is driven by executing our goals and achieving positive financial results. For employees, growth of shareholder value provides financial security for our families and the pursuit of happiness for our future.

The key to our success is sustaining a winning culture, which means patients first.

Our patients and our customers are the motivation for all that we do, and achieving our mission is dependent on their well-being. We must always act with integrity and honor and demand the best of ourselves. We work hard. We have faith in each other, and we have fun celebrating the patient success stories. These are our four principles, and these principles guide our future.

EX-99.6

Exhibit 99.6

“I am Abiomed. I am Heart Recovery” Transcript

“I am Abiomed” repeated in multiple languages as voiceover in introduction.

In English: “I am Abiomed.”

In English: “I am heart recovery.”

In German: “Together with my Teammates…”

In English: “…we put patients first and are committed to recovering hearts.”

In German “…and are committed to savings lives”

In English: “We sustain our winning culture by acting with honor and integrity in all that we do.”

In German: “We are dedicated to ensuring that Abiomed’s growth as the standard of care”

In English: “… is based on innovation, improving outcomes

In Japanese: “…and appropriate use.”

In English: “ We advocate for every patient to receive the care we desire for our own family and friends.”

In German: “And we recognize the potential benefits of other products and treatments.

In Japanese: “We inspire each other…”

In English: ” … and have the courage and grit to explore new ideas and approaches

In Japanese:“… that can change the world.”

In Japanese: ““We work together to achieve our goals. And demand the best of ourselves.”

In English: “We are dedicated to continuous improvement…”

In German: “…and strive for perfection.”

In English: “And we always seek opportunities to lead, manage, adapt and execute.”

In English: I am Abiomed.

In Japanese: “I am Abiomed”

In Japanese: “I am Abiomed”

In German: “ I am Abiomed”

In German: “ I am Abiomed”

In English: Patients First.

EX-99.7

Exhibit 99.7

Approved Supplier Messaging Kit

For Internal Use Only - Do Not Forward or Distribute

TALKING POINTS

• Good morning – I would like to contact you personally about the exciting news we announced today.

• This morning, we announced an agreement has been reached for Abiomed to become part of Johnson & Johnson.

• For certain key vendor relationships: Based on our long-standing partnership, I want to personally assure you that in terms of our working relationship, it’s business as usual.

• This transaction is all about improving our value to patients and saving more lives. By combining our technology and global team with Johnson & Johnson MedTech’s scale and resources, we can accelerate the timeline for making heart recovery the global standard of care.

• One of our key priorities is maintaining continuity and stability, and we’re pleased to have a lot of clarity at this point about how we’ll operate as part of Johnson & Johnson:

• Abiomed will be a wholly owned subsidiary of Johnson & Johnson MedTech and retain its name

• Andrew Greenfield, our current chief commercial officer, will run the standalone Abiomed business

• Mike Minogue, our CEO, will advise during the transition

• Our products will remain the same

• Your point of contact will remain the same

• Existing contracts will continue unchanged under our new ownership

• For other vendor relationships: At this time, we do not anticipate any changes for our suppliers as a result of this transaction.

• In terms of next steps, acquisitions like this one require regulatory approval and typically take several months to finalize and close. Until then it is business as usual.

• We will keep you updated about any key developments between now and the close. If you have any questions in the meantime, do not hesitate to reach out.

• Thank you for your continued partnership and support.

Q&A FOR SUPPLIERS

1. What does this mean for suppliers?

It is business as usual. At this time, we do not anticipate any changes for our suppliers as a result of this transaction.

2. What will happen to existing contracts?

Existing contracts will continue under the new ownership.

3. Will points of contact change?

We are not anticipating any changes to your point of contact as a result of the acquisition.

WRITTEN COMMUNICATION

Dear [NAME],

This morning, we announced an agreement has been reached for Abiomed to become part of Johnson & Johnson. This is exciting news for our company and will greatly benefit our patients and partners. You can read the press release here.

As a valued partner, I would like to reach out to you to make sure you understand that in terms of our relationship, nothing changes. It is business as usual.

Ensuring continuity and stability is a key priority for both of our organizations. To that end, Abiomed will be a wholly owned subsidiary of Johnson & Johnson MedTech, and Abiomed’s current chief commercial officer, Andrew Greenfield, will run the standalone Abiomed business. Our products will remain the same, your point of contact will remain the same and existing contracts will continue unchanged.

In terms of next steps, acquisitions like this one require regulatory approval and typically take several months to finalize and close. We anticipate closing in Q1 2023 and will, in our public filings, provide updates about any key developments between now and the close. If you have any questions in the meantime, do not hesitate to reach out.

We thank you for your continued partnership and support and hope you share our excitement about the future.

Best regards,

LEGEND FOR COMMUNICATIONS

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the Securities and Exchange Commission (“SEC”) by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

EX-99.8

Exhibit 99.8

Approved Physician Messaging Kit

For Internal Use Only - Do Not Forward or Distribute

TALKING POINTS

• Good morning – I would like to let you know right away about some exciting news that we announced today.

• An agreement has been reached for Abiomed to become part of Johnson & Johnson, becoming a standalone business within its organization.

• I want to make it clear that nothing changes about our products or our partnership with you.

• This transaction is all about improving our value to patients, physicians, and hospitals, and saving more lives. By combining our technology and global team with Johnson & Johnson’s scale and resources, we can accelerate the timeline for making heart recovery the global standard of care.

• Together, we will recover hearts and save lives faster than we could ever do on our own.

• Like you, one of our key priorities is maintaining continuity and stability, and we’re pleased to have a lot of clarity at this point about how we’ll operate as part of Johnson & Johnson:

• Abiomed will be a wholly owned subsidiary of Johnson & Johnson

• Andrew Greenfield, our current chief commercial officer, will run the standalone Abiomed business.

• Mike Minogue will stay on as an advisor during the transition period.

• Our products will remain the same.

• Your point of contact will remain the same.

• We will continue to offer 24x7 onsite, on call and online support to hospitals.

• Even our name is staying the same.

• Additionally – and equally important – our two organizations share common values, purpose and a Patients First mindset. I know a lot of companies say this, but we live it.

• We have the I Am Abiomed Patients First Commitment, and Johnson & Johnson has its world-renowned “Our Credo,” which put the needs and well-being of the people the company serves first.

• In terms of next steps, acquisitions like this one require regulatory approval, and typically take several months to finalize and close.

• We will keep you updated about any key developments between now and the close. If you have any questions in the meantime, do not hesitate to reach out.

• Thank you for your continued partnership and support. I am always here if you have any questions or concerns.

Q&A for PHYSICIANS

1. Will Abiomed continue to offer 24x7 onsite and online support to hospitals?

Yes. The service we provide our customers and patients is one of Abiomed’ key differentiators.

2. Will any changes be made to our line of products?

Abiomed’s products will remain the same.

3. Will points of contact change?

We are not anticipating any changes to your point of contact as a result of the acquisition.

WRITTEN COMMUNICATION

Dear [NAME],

This morning, we announced an agreement has been reached for Abiomed to become part of Johnson & Johnson. This is exciting news for our company and will greatly benefit our patients and partners. You can read the press release here. Importantly, this transaction will not change anything with respect to our products, clinical support, clinical trial programs, or our partnership with you.

By combining Abiomed’s proven technology and talented, dedicated team of employees with Johnson & Johnson’s global scale, financial strength, robust clinical expertise and manufacturing capabilities, we can accelerate our timeline for heart recovery for patients all over the world. Together, we will recover hearts and save even more lives faster than we could ever do on our own.

Our two organizations have common values, purpose and Patients First mindsets. We have the I Am Abiomed Patients First Commitment. Johnson & Johnson has its “Our Credo,” which put the needs and well-being of the people the company serves first.

Ensuring continuity and stability is a key priority for both of our organizations – as we know it is for you. To that end, Abiomed will be a wholly owned subsidiary of Johnson & Johnson MedTech. Mike Minogue will serve as a consultant to assure a smooth transition and Abiomed’s current chief commercial officer, Andrew Greenfield, will run the standalone Abiomed business. Our products will remain the same, your point of contact will remain the same, and we will continue to offer 24x7 onsite, on call, and online support to hospitals. Even the Abiomed name will stay the same.

In terms of next steps, acquisitions like this one require regulatory approval, and typically take several months to finalize and close. We anticipate closing in Q1 2023 and will, in our public filings, provide updates about any key developments between now and the close. If you have any questions in the meantime, do not hesitate to reach out to me directly.

For years, and with your help, we have dreamed of making heart recovery the global standard of care. Combining the resources of Abiomed and Johnson & Johnson will allow us to make that dream come true faster than we ever thought possible.

We thank you for your continued partnership and support and hope you share our excitement about the future.

Best regards,

LEGEND FOR COMMUNICATIONS

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to

time in documents filed with the Securities and Exchange Commission (“SEC”) by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

EX-99.9

Exhibit 99.9

Approved Government or Association Messaging Kit

For Internal Use Only - Do Not Forward or Distribute

TALKING POINTS

• Good morning – I would like to let you know right away about some exciting news that we announced today.

• An agreement has been reached for Abiomed to become part of Johnson & Johnson, becoming a standalone business within its organization.

• This transaction is all about improving our value to patients and saving more lives. By combining our technology and global team with Johnson & Johnson MedTech’s scale and resources, we can accelerate the timeline for making heart recovery the global standard of care.

• Together, we will recover hearts and save lives faster than we could ever do on our own.

• Both companies are committing to maintaining continuity and stability, and we’re pleased to have a lot of clarity at this point about how we’ll operate as part of Johnson & Johnson:

• Abiomed will be a wholly owned subsidiary of Johnson & Johnson MedTech

• Mike Minogue, our CEO, will serve as a consultant to assure a smooth transition and Andrew Greenfield, our current chief commercial officer, will run the standalone Abiomed business

• Our products will remain the same

• We will maintain our current offices and manufacturing facilities, including our Danvers, MA, headquarters

• We will continue to support local communities and organizations as we have always done

• We will continue to be called Abiomed

• Given the commitments we have already received from Johnson & Johnson, we do expect little change for our people. Our leadership team is committed to be transparent and treat all employees fairly and respectfully.

• In terms of next steps, acquisitions like this one require regulatory approval, and typically take several months to finalize and close. We will keep you updated about any key developments between now and the close. If you have any questions in the meantime, do not hesitate to reach out.

• Thank you for your continued partnership and support.

WRITTEN COMMUNICATION

Dear [NAME],

This morning, we announced an agreement has been reached for Abiomed to become part of Johnson & Johnson. This is exciting news for our company and will greatly benefit our patients and partners. You can read the press release here.

By combining Abiomed’s proven technology and talented global team of employees with Johnson & Johnson’s scale and resources, we can accelerate the timeline for making heart recovery the global standard of care. Together, we will recover hearts and save lives faster than we could ever do on our own.

We will continue to honor our commitments to our patients, our employees and our communities. Our two organizations share common values, purpose and Patients First mindsets. We have the I Am Abiomed Patients First Commitment. Jupiter has its “Our Credo,” which puts the needs and well-being of the people the company serves first.

Johnson & Johnson views Abiomed as an important new growth platform and so ensuring continuity and stability is a key priority for both of our organizations. To that end, Abiomed will be a wholly owned subsidiary of Johnson & Johnson MedTech, and Abiomed’s current chief commercial officer, Andrew Greenfield, will run the standalone Abiomed business.

As part of Johnson & Johnson MedTech, we will maintain our current offices and manufacturing facilities, including our Danvers, MA, headquarters, and we will continue to be called Abiomed. Johnson & Johnson prides itself on employee volunteerism and support of its local communities, and we will continue to support local communities and organizations as we have always done.

We expect – and Johnson & Johnson has reinforced this view – little change for our people. Our leadership team is committed to be transparent and treat all employees fairly and respectfully.

In terms of next steps, acquisitions like this one require regulatory approval, and typically take several months to finalize and close. We will keep you updated about any key developments between now and the close. If you have any questions in the meantime, do not hesitate to reach out.

For years, we have dreamed of making heart recovery the global standard of care. Combining the resources of Abiomed and Johnson & Johnson MedTech will allow us to make that dream come true faster than we ever thought possible.

Best regards,

LEGEND FOR COMMUNICATIONS

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the Securities and Exchange Commission (“SEC”) by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

EX-99.10

Exhibit 99.10

Approved Business Partner Messaging Kit

For Internal Use Only - Do Not Forward or Distribute

TALKING POINTS

• Good morning – I would like to contact you personally about the exciting news we announced today.

• An agreement has been reached for Abiomed to become part of Johnson & Johnson, becoming a standalone business within its organization.

• I want to personally assure you that in terms of our relationship, it’s business as usual. This agreement will not have any impact.

• This transaction is all about improving our value to patients and saving more lives. By combining our technology and global team with Johnson & Johnson MedTech’s scale and resources, we can accelerate the timeline for making heart recovery the global standard of care.

• One of our key priorities is maintaining continuity and stability, and we’re pleased to have a lot of clarity at this point about how we’ll operate as part of Johnson & Johnson:

• Abiomed will be a wholly owned subsidiary of Johnson & Johnson MedTech and retain its name

• Andrew Greenfield, our current chief commercial officer, will run the standalone Abiomed business

• Our products will remain the same

• Existing contracts and partnerships will continue unchanged under our new ownership

• Your point of contact will remain the same

• In terms of next steps, acquisitions like this one require regulatory approval, and typically take several months to finalize and close. Until then it is business as usual.

• We will keep you updated about any key developments between now and the close. If you have any questions in the meantime, do not hesitate to reach out.

• Thank you for your continued partnership and support.

WRITTEN COMMUNICATION

Dear [NAME],

This morning, we announced an agreement has been reached for Abiomed to become part of Johnson & Johnson. This is exciting news for our company and will greatly benefit our patients and partners. You can read the press release here.

As a valued partner, we would like to reach out to you to make sure you understand this changes nothing with our relationship. It is business as usual.

Ensuring continuity and stability is a key priority for both of our organizations – as we know it is for you. To that end, Abiomed will be a wholly owned subsidiary of Johnson & Johnson MedTech. Mike Minogue will serve as a consultant to assure a smooth transition and Abiomed’s current chief commercial officer, Andrew Greenfield, will run the standalone Abiomed business. Your point of contact will remain the same,

In terms of next steps, acquisitions like this one require regulatory approval, and typically take several months to finalize and close. We anticipate closing in Q1 2023 and will, in our public filings, provide updates about any key developments between now and the close. If you have any questions in the meantime, do not hesitate to reach out.

We thank you for your continued partnership and support and hope you share our excitement about the future.

Best regards,

LEGEND FOR COMMUNICATIONS

Additional Information and Where to Find it

The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of ABIOMED, Inc. At the time the offer is commenced, Johnson & Johnson and its merger subsidiary, Athos Merger Sub, Inc., will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and ABIOMED, Inc. will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. ABIOMED, Inc. stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of ABIOMED, Inc. In addition, all of these materials (and all other materials filed by ABIOMED, Inc. with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by ABIOMED, Inc. at https://investors.abiomed.com/investors/financials/sec-filings/default.aspx.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for ABIOMED’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; any potential strategic benefits, synergies or opportunities expected as a result of the proposed transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of ABIOMED’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the ABIOMED’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from ABIOMED’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of ABIOMED into Johnson & Johnson subsequent to the closing of the transaction and the timing of such integration; other business effects, including the effects of industry, economic or political conditions outside of ABIOMED’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the Securities and Exchange Commission (“SEC”) by ABIOMED, including ABIOMED’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by ABIOMED and the tender offer documents to be filed by Johnson & Johnson and Athos Merger Sub, Inc. The effects of the COVID-19 pandemic may give rise to risks that are currently unknown or amplify the risks associated with many of these factors.

ABIOMED is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.